Wong N - Search Results

1

APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.

Chen H, Wong CC, Liu D, Go MYY, Wu B, Peng S, Kuang M, Wong N, Yu J. Chen H, et al. Among authors: wong cc, wong n. Theranostics. 2019 Jul 9;9(18):5246-5260. doi: 10.7150/thno.34713. eCollection 2019. Theranostics. 2019. PMID: 31410213 Free PMC article.

2

Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells.

Wong N, Chan KY, Macgregor PF, Lai PB, Squire JA, Beheshti B, Albert M, Leung TW. Wong N, et al. Clin Cancer Res. 2005 Feb 1;11(3):1319-26. Clin Cancer Res. 2005. PMID: 15709204

3

Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma.

Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B, Squire JA, Wong N. Ip WK, et al. Among authors: wong nl, wong n. Cancer Lett. 2007 Jun 8;250(2):284-91. doi: 10.1016/j.canlet.2006.10.012. Epub 2006 Nov 28. Cancer Lett. 2007. PMID: 17126992

4

RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma.

Cheng AS, Wong N, Tse AM, Chan KY, Chan KK, Sung JJ, Chan HL. Cheng AS, et al. Among authors: wong n. Cancer Lett. 2007 Aug 8;253(1):43-52. doi: 10.1016/j.canlet.2007.01.004. Epub 2007 Feb 12. Cancer Lett. 2007. PMID: 17296261

5

Identification of PFTAIRE protein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells.

Pang EY, Bai AH, To KF, Sy SM, Wong NL, Lai PB, Squire JA, Wong N. Pang EY, et al. Among authors: wong nl, wong n. Hepatology. 2007 Aug;46(2):436-45. doi: 10.1002/hep.21691. Hepatology. 2007. PMID: 17559150

6

MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1.

Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. Wong QW, et al. Among authors: wong n. Gastroenterology. 2008 Jul;135(1):257-69. doi: 10.1053/j.gastro.2008.04.003. Epub 2008 Apr 11. Gastroenterology. 2008. PMID: 18555017

7

Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis.

Cheng IK, Ching AK, Chan TC, Chan AW, Wong CK, Choy KW, Kwan M, Lai PB, Wong N. Cheng IK, et al. Among authors: wong ck, wong n. J Pathol. 2010 Feb;220(3):348-60. doi: 10.1002/path.2644. J Pathol. 2010. PMID: 19927314

8

MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling.

Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N. Wong QW, et al. Among authors: wong n. Clin Cancer Res. 2010 Feb 1;16(3):867-75. doi: 10.1158/1078-0432.CCR-09-1840. Epub 2010 Jan 26. Clin Cancer Res. 2010. PMID: 20103675

9

Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers.

Leung WK, Ching AK, Wong N. Leung WK, et al. Among authors: wong n. Mol Cell Biochem. 2011 Apr;350(1-2):201-6. doi: 10.1007/s11010-010-0699-8. Epub 2010 Dec 24. Mol Cell Biochem. 2011. PMID: 21184254

10

Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.

Zhou Q, Ching AK, Leung WK, Szeto CY, Ho SM, Chan PK, Yuan YF, Lai PB, Yeo W, Wong N. Zhou Q, et al. Among authors: wong n. Int J Oncol. 2011 Mar;38(3):721-31. doi: 10.3892/ijo.2011.902. Epub 2011 Jan 14. Int J Oncol. 2011. PMID: 21240457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,519 results

Search Page

Filters